e-therapeutics veröffentlicht präklinische Daten zu ETX-148 auf dem EAHAD 2025 LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, ein Unternehmen mit Fokus auf der Integration von Rechenleistung und biologischen Daten für die Erforschung lebensverändernder RNAi-Arzneimittel, gab heute bekannt, dass es auf dem Jahreskongress der European Association for Haemophilia and Allied Disorders (EAHAD) vom 4.-7. Februar 2025 neue präklinische Daten präsentieren wird, die nachweislich die Wirksamkeit und Sicherheit von ETX-148 bei Hämophilie A und B in Mausmodellen zeigen. ETX-148 wird zu...
e-therapeutics présentera des données précliniques relatives à l’ETX-148 lors de l’édition 2025 du Congrès annuel de l’EAHAD LONDRES, 05 févr. 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, une entreprise qui conjugue la puissance informatique aux données biologiques en vue de mettre au point des nouveaux médicaments ARNi, annonce ce jour son intention de présenter de nouvelles données précliniques démontrant l’efficacité et la sécurité d’emploi de l’ETX-148 dans des modèles murins d’hémophilie A et B lors du Congrès annuel de l’Association européenne pour l’hémophilie et les troubles appar...
e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025 LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will present new preclinical data demonstrating efficacy and safety of ETX-148 in murine models of haemophilia A and B at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), 4th-7th February 2025. ETX-148 is being developed for the treatment of bleeding disorders and is currently progressin...
e-therapeutics Announces Business Updates and Interim Results LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business updates, including its unaudited interim results for the six months to 31st July 2024. Ali Mortazavi, CEO, said: “We continue to make strong and rapid progress towards becoming a clinical-stage biotech company, as we advance our pipeline of novel GalOmic therapies, aiming to file our first IND submission in 2025. I am also excited abou...
JP Jenkins Ltd e-therapeutics plc, Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors 16-Jul-2024 / 16:14 GMT/BST The issuer is solely responsible for the content of this announcement. 16th July 2024 ISIN: GB00B2823H99 JPJ:ETX e-therapeutics plc ("e-therapeutics" or "ETX" or the "Company") Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors London, UK, 16 July 2024 – e-therapeutics plc, a company integrating computational power and biological data to discover life-trans...
JP Jenkins Ltd e-therapeutics announces completion of £28.90 million fundraise 03-Jul-2024 / 11:49 GMT/BST The issuer is solely responsible for the content of this announcement. 3rd July 2024 ISIN: GB00B2823H99 JPJ:ETX e-therapeutics plc ("e-therapeutics" or "ETX" or the "Company") e-therapeutics announces completion of £28.90 million fundraise London, UK, 3 July 2024 - e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, is pleased to announce that it has completed its £28.90 mill...
For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This is quite unusual for healthcare stocks. Apart from the general economic influences, which have made institutions more risk-averse, there was a common knowledge that several companies were in need of additional working capital; so, share prices were marked down in anticipation of equity raises. However, the small- and mid-cap life sciences sector has alway...
JP Jenkins Ltd Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors 23-May-2024 / 08:32 GMT/BST The issuer is solely responsible for the content of this announcement. 23rd May 2024 JPJ:ETX ISIN: GB00B2823H99 e-therapeutics plc ("e-therapeutics" or “ETX” or the "Company") Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors London, UK, 23 May 2024 – e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, is pleased announce the appointment...
JP Jenkins Ltd e-therapeutics plc shares now trading on JP Jenkins 09-May-2024 / 07:30 GMT/BST The issuer is solely responsible for the content of this announcement. 9th May 2024 JPJ: ETX ISIN: GB00B2823H99 e-therapeutics plc ("e-therapeutics" or "ETX" or the "Company") Shares now trading on JP Jenkins London, UK, 9th May 2024 – e-therapeutics plc (AIM: ETX), a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announces its shares (“ETX”) () have been admitted to trade on JP Jenkins share dealing plat...
Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our web...
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (...
Edison Investment Research Limited Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery 13-Nov-2023 / 09:05 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 13 November 2023 Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery e-therapeutics reported H1 FY24 results (to end-July 2023), reaffirming its commitment to integrating its computational and hepatocyte biology expertise to develop short interfering RNA (siRNA) therapies. The key half-year development was the pr...
e-therapeutics reported H1 FY24 results (to end-July 2023), reaffirming its commitment to integrating its computational and hepatocyte biology expertise to develop short interfering RNA (siRNA) therapies. The key half-year development was the proof-of-concept (PoC) data for two preclinical assets for the treatment of cardiometabolic disease and haemophilia, with further updates forthcoming. We view these pipeline updates, especially in segments with increased interest, as positive. Management co...
2nd November 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje...
Artificial intelligence (AI) continues to accelerate at full speed, first by imitating the workings of a human brain and now it is drawing concepts of evolution, sometimes with synthetic data, artificially manufactured for training purposes or for privacy protection, and sometimes not even with human intervention. In this note, we examine how AI is being developed and applied by the NHS and UK mid/small cap companies for the benefit of human health and wellbeing. AI in drug discovery and devel...
e-therapeutics is a biotech leveraging its validated computational biology platform to identify novel, liver-associated targets and expand its internal pipeline of short interfering RNA (siRNA or RNAi) therapeutics. In addition to the advantages of focusing on a single cell type (hepatocytes), the company’s recent strategic commitment to large language model (LLM) technologies has the potential to provide accelerated access to effective new drugs. RNAi medicines are a rapidly evolving drug class...
4th May 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objective...
07 February 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objec...
Drug discovery and development requires colossal upfront investment. The process typically takes over a decade. A large number of product candidates fail to prove efficacy or safety during preclinical and clinical research phases or fail to pass regulatory scrutiny. According to Deloitte, the average cost of drug discovery and development increased over 80% between 2010 and 2018 from $1.188bn to $2.168bn, CAGR 7.8%, per successfully launched drug.
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.